Menu

Elizabeth A. Kolar, Ph.D.

Dr. Elizabeth Kolar is a technical specialist on the firm's Intellectual Property Transactional team, focusing her work efforts on biotechnology and life sciences. Dr. Kolar’s research background is extremely diverse, working with organisms ranging from plants to mammalian cell lines. Through her research experience she has gained an expertise in several sub-disciplines including: biochemistry, molecular biology, genetics, physiology, and cellular biology. Dr. Kolar’s graduate dissertation focused on the novel role of an acyl-CoA synthetase in the development and progression of metastatic brain cancer.

Prior to joining the firm, Dr. Kolar worked as a postdoctoral fellow in the Department of Biophysics and Physiology at Boston University School of Medicine. There, she was granted a T32 research fellowship and investigated the role of the putative fatty acid transporter CD36 in pancreatic beta-cells and the development of Type 2 Diabetes. As a postdoctoral fellow at The Johns Hopkins University School of Medicine, she was a part of a large-scale collaboration between the Kennedy Krieger Institute and a pharmaceutical company, where she and colleagues investigated two drug candidates for the treatment of X-linked Adrenoleukodystrophy. 

Honors

  • T32 Post-Doctoral Fellowship, National Institutes of Health, 2017-2018
  • F31 Pre-Doctoral Fellowship, National Institute of Neurological Disease and Stroke, 2011-2014
  • Graduate Student and Postdoctoral Travel Award, ASBMB, 2012
  • Young Botanist of the Year, Botanical Society of America, 2007
  • Department of Biological Sciences Faculty Award, Salisbury University, 2007

Professional Affiliations

  • American Association for the Advancement of Science, Member
  • American Society of Biochemistry and Molecular Biology, Member

Publications

  • ACSVL3 depletion decreases glioma cell proliferation by altering the cell cycle and not by increasing apoptosis or autophagy.  In preparation. 2018.

  • Very long chain acyl-CoA synthetase 3 (ACSVL3) increases sphingolipid levels in U87 glioma cells regulating signaling from receptor tyrosine kinases. In preparation. 2018.

  • BLM helicase ortholog Sgs1 is a central regulator of meiotic recombination intermediate metabolism.  Mol Cell1: 43-53, 2012. 

  • Ipl1/Aurora B kinase coordinates synaptonemal complex disassembly with cell cycle progression and crossover formation in budding yeastmeiosis.  Genes Dev.  18: 2237-51, 2009.

  • A noncanonical bromodomain in the AAA ATPase protein Yta7 directs chromosomal positioning and barrier chromatin activity.   Mol Cell Biol17: 4604-11, 2009.          

     

Presentations

  • Understanding the Role of Pancreatic CD36 in the Development of Type 2 Diabetes, Experimental Biology, ASBMB Annual Meeting, San Diego, CA, 2018
  • Importance of Very Long Chain Acyl-CoA Synthetase 3 (ACSVL3) in Cholesterol Homeostasis and Lipid Raft Signaling in U87 Glioma Cells, Experimental Biology, ASBMB Annual Meeting, San Diego, CA, 2012
  • Quantification of Nordihydroguaiaretic Acid (NDGA) in the Three Ploidy Levels of Larrea tridentata, Botanical Society of America Annual Meeting, Chicago, IL, 2007
  • Development of Microsatellite Markers in Larrea (Zygophyllaceae): A New Way to Investigate the Evolutionary History of Larrea, Botanical Society of America Annual Meeting, Austin, TX, 2005
Photo of Elizabeth A. Kolar, Ph.D.
  • Boston

    28 State Street
    Suite 700
    Boston, MA 02109
F: 857.300.4001

Assistant

Lyn Brathwaite
857.300.4073

Education

The Johns Hopkins University School of Medicine, Ph.D. Biological Chemistry, 2016

Salisbury University, B.S. Cellular and Molecular Biology, 2007